Core Insights - Teva Pharmaceutical Industries Ltd. reported third-quarter earnings that exceeded expectations, driven by strong sales of innovative therapies and an improved full-year outlook, resulting in a share price surge of over 17% in intra-day trading [1] Financial Performance - The company posted adjusted earnings of $0.78 per share, surpassing analyst forecasts of $0.68 [1] - Revenue increased by 3% year over year to $4.48 billion, exceeding the consensus estimate of $4.36 billion, with 1% growth in local currency [1] Innovative Medicine Portfolio - Teva's innovative medicine portfolio, including AUSTEDO, AJOVY, and UZEDY, saw segment revenue rise by 33% year over year in local currency to $830 million [2] - AUSTEDO was the primary driver of growth, achieving $618 million in global sales, reflecting a 38% increase in local currency [2] Future Outlook - Based on strong momentum, Teva raised its 2025 AUSTEDO revenue forecast by $50 million to $100 million, establishing a new target range of $2.05 billion to $2.15 billion [3] - The company tightened its full-year revenue guidance to a range of $16.8 billion to $17.0 billion and raised the low end of its adjusted EPS range to $2.55–$2.65 from $2.50–$2.65 [3] Operational Efficiency - Teva's non-GAAP operating margin improved to 28.9%, an increase of 86 basis points from the previous year, keeping the company on track to achieve its 30% target by 2027 under its "Pivot to Growth" strategy [4]

Q3 2025 Financial Performance - Revenues reached $4480 million, a 3% increase year-over-year[21, 93] - Adjusted EBITDA was $1400 million, up by 6% compared to the previous year[21] - Non-GAAP EPS increased by 14% to $078[21] - Free Cash Flow was $500 million[21] AUSTEDO Performance and Outlook - AUSTEDO U S revenues grew by 38% year-over-year to $601 million in Q3 2025[32] - AUSTEDO global revenues grew by 38% year-over-year to $618 million in Q3 2025[25] - The company reaffirmed its 2027 sales target for AUSTEDO at over $25 billion[29, 58] Pipeline and Strategic Updates - UZEDY revenues in Q3 2025 reached $43 million, a 24% increase year-over-year[25, 36] - The company reaffirmed its 2025 revenue outlook for UZEDY at $190 million - $200 million[35] - Global revenues for AJOVY reached $168 million in Q3 2025, a 19% increase year-over-year[25, 46] - The company is targeting olanzapine LAI FDA submission in Q4 2025[48, 63]

For an accessible version of this Press Release, please visit www.tevapharm.com Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues increased 5% in U.S. dollars or 3% in LC. United States segment increased by 12%; Europe segment decreased by 10% in LC; and International Markets segment decreased by 10% in LC, or increased by 2% in LC excluding Japan BV in Q3 2024, all ...

Wall Street analysts expect Teva Pharmaceutical Industries Ltd. (TEVA) to post quarterly earnings of $0.68 per share in its upcoming report, which indicates a year-over-year decline of 1.5%. Revenues are expected to be $4.35 billion, up 0.4% from the year-ago quarter.Over the last 30 days, there has been an upward revision of 0.4% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the c ...

Core Insights - Teva Pharmaceutical Industries Limited is recognized as a promising stock under $100, with BofA raising its price target to $24 from $22 while maintaining a Buy rating [1] - The company has achieved its 10th consecutive quarter of year-over-year revenue growth, driven by its Pivot to Growth Strategy, targeting a 30% operating profit margin by 2027 [2] - Teva's innovative product portfolio has seen significant growth, with total revenues for Q2 2025 reaching $4.2 billion, marking a ~1% increase in local currency [2][3] Financial Performance - Teva's innovative portfolio collectively grew by ~26%, leading to an increased revenue outlook for key products [3] - AUSTEDO revenues were $498 million globally in Q2, up ~19% globally and ~22% in the US, with the 2025 revenue outlook raised to $2,000 to $2,050 million [3] - AJOVY global revenues reached $155 million, up ~31%, with the outlook increased to $630 to $640 million [3] - UZEDY revenues accelerated by ~120% to $54 million, with the outlook raised to $190 to $200 million [3] Strategic Initiatives - Teva is executing its Pivot to Growth Strategy, which has been a key driver of its recent revenue growth [2][3] - The company is focused on achieving a 30% operating profit margin by 2027 as part of its long-term strategy [2]

Core Insights - Teva Pharmaceutical Industries Ltd. reported revenue of $4.18 billion for the quarter ended June 2025, reflecting a year-over-year increase of 0.3% but a revenue surprise of -2.47% compared to the Zacks Consensus Estimate of $4.28 billion [1] - The earnings per share (EPS) for the quarter was $0.66, surpassing the consensus estimate of $0.63, resulting in an EPS surprise of +4.76% [1] Financial Performance Metrics - Teva's stock has returned -0.6% over the past month, while the Zacks S&P 500 composite has increased by +3.4% [3] - The company holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3] Geographic Revenue Breakdown - Revenue from Europe was $1.3 billion, exceeding the average estimate of $1.25 billion, with a year-over-year change of +7% [4] - Revenue from International Markets was $495 million, below the average estimate of $602.4 million, representing a year-over-year decline of -16.5% [4] - Revenue from the United States was $2.15 billion, slightly below the estimated $2.19 billion, with a year-over-year increase of +1.9% [4] - Revenue from Anda in the United States was $365 million, surpassing the average estimate of $358.28 million, but showing a year-over-year decline of -2.1% [4] - Revenue from COPAXONE in Europe was $50 million, exceeding the average estimate of $40.5 million, with a year-over-year decline of -5.7% [4] - Revenue from respiratory products in Europe was $55 million, in line with the estimate of $55.07 million, reflecting a year-over-year decrease of -3.5% [4] - Revenue from generic products in International Markets was $410 million, below the average estimate of $478.57 million, with a year-over-year decline of -15.6% [4] - Revenue from COPAXONE in International Markets was $7 million, significantly below the estimate of $10.83 million, representing a year-over-year decline of -50% [4] - Revenue from AJOVY in the United States was $63 million, exceeding the average estimate of $50.8 million, with a year-over-year increase of +50% [4] - Total revenue from COPAXONE was $119 million, above the average estimate of $101.85 million, but showing a year-over-year decline of -19.6% [4] - Total revenue from other sources was $232 million, below the average estimate of $259.03 million, with a year-over-year increase of +118.9% [4] - API sales to third parties amounted to $135 million, below the average estimate of $156.49 million, with a year-over-year decline of -10.6% [4]

Financial Data and Key Metrics Changes - Revenues increased to $4.2 billion, up 1%, marking the tenth consecutive quarter of growth [8][10] - Adjusted EBITDA rose by 7%, and non-GAAP EPS increased by 10% [9] - Net debt to EBITDA ratio is just over 3 times [9][46] Business Line Data and Key Metrics Changes - AUSTEDO revenue reached approximately $495 million, up 22% [13] - ECETI revenue surged by 120% to $54 million [12] - AJOVY revenue grew by 31% to $155 million [12] - Global Generics business declined by 2%, reflecting strong prior year comparisons [21] - TAPI revenue decreased by 11%, attributed to seasonality and timing of shipments [12] Market Data and Key Metrics Changes - U.S. generics business showed a decline due to tough prior year comparisons and timing of shipments [22][24] - EU generics business grew by 8% in the prior year, but growth has slowed due to product launches and competitive stockouts [24] Company Strategy and Development Direction - The company is focused on a "pivot to growth" strategy initiated in 2023, emphasizing innovative products and generics stability [6][27] - A target of $700 million in net savings by 2027 has been set, with 20% of this already achieved [27][40] - The company aims to achieve a 30% operating margin by 2027 [40][48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2025 guidance despite uncertainties around U.S. tariffs on pharmaceuticals [41][52] - The innovative portfolio is expected to over-deliver, with raised guidance for AUSTEDO, YEUSEDI, and AJOVY [30][51] - The company anticipates a flat to low single-digit growth in generics for the full year [25][52] Other Important Information - The company has divested its Japanese business, which is consistent with its strategy to focus on profitable growth [42] - Free cash flow grew by 47% to $476 million, driven by higher net income and working capital improvements [45] Q&A Session Summary Question: Insights on AUSTEDO and IRA negotiations - Management refrained from commenting on IRA negotiations due to ongoing discussions with CMS [63][64] Question: Impact of tariffs announced in Europe - Management is assessing the details of the tariffs and believes they have mitigated potential impacts on the business [65][66] Question: AUSTEDO BID to XR conversion timeline - Management indicated that while new patients are converting to XR, it will take time for the majority of patients to transition [72][75] Question: Clarification on tariff impacts and exclusions - Management acknowledged uncertainty regarding the specifics of tariff exclusions and is awaiting further clarity [81][84] Question: Updates on DUVAKITU and Phase II data - Management confirmed that Phase III studies for DUVAKITU are on track and Phase II data will be presented in 2026 [90][91] Question: Revenue guidance related to generic Revlimid - Management clarified that revenue guidance is influenced by the performance of generic Revlimid, particularly in Q4 [103]

Financial Data and Key Metrics Changes - Revenues increased to $4.2 billion, up 1%, marking the tenth consecutive quarter of growth [7][8] - Adjusted EBITDA rose by 7%, and non-GAAP EPS increased by 10% [7][41] - Net debt to EBITDA ratio is just over 3 times [7][44] Business Line Data and Key Metrics Changes - AUSTEDO revenue reached approximately $495 million, up 22% [11] - YUCEDDI revenue increased by 120% to $190 million to $200 million [12] - AJOVY revenue guidance raised to $630 million to $640 million, reflecting a strong 31% growth [16] - Global Generics business declined by 2%, impacted by strong prior year comparisons [10][20] Market Data and Key Metrics Changes - U.S. generics business growth was hindered by prior year comparisons and timing of shipments [21][22] - EU generics business grew by 8% in the prior year, but growth has slowed due to product launches and competitive stockouts [22] Company Strategy and Development Direction - The company is focused on a pivot to growth strategy, emphasizing innovation and a strong pipeline [5][25] - A transformation program aims to generate $700 million in net savings by 2027 [25][46] - The company is transitioning to a biopharma model, with a target of achieving a 30% operating margin by 2027 [37][45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2025 guidance despite uncertainties around U.S. tariffs on pharmaceuticals [38][50] - The innovative portfolio is expected to over-deliver, with combined revenue guidance for AUSTEDO, YUCEDDI, and AJOVY raised by approximately $95 million [28][49] - Management remains optimistic about the long-term growth trajectory, driven by innovative products and a stable generics business [55][58] Other Important Information - The company has seen a significant improvement in its balance sheet, with credit rating upgrades from major agencies [37][44] - Free cash flow grew by 47% to $476 million, driven by higher net income and working capital improvements [43] Q&A Session Summary Question: Insights on AUSTEDO and IRA negotiations - Management declined to comment on IRA negotiations due to ongoing discussions with CMS [62][63] Question: Impact of tariffs announced in Europe - Management indicated that they are assessing the details of the tariffs and have prepared mitigation plans [64][66] Question: AUSTEDO's BID to XR conversion - Management noted that while new patients are converting to XR, it will take time for the majority of patients to switch [72][75] Question: Clarification on tariff impacts and generics - Management stated that they do not foresee a meaningful short-term impact from tariffs due to their flexible supply chain [79][80] Question: Updates on DUVAKITU and Phase II data - Management confirmed that the Phase III studies for DUVAKITU are on track and that Phase II data will be presented in 2026 [90][91] Question: Revenue guidance for generic Revlimid - Management acknowledged that revenue guidance is fluid and will depend on the performance of generic Revlimid in the latter half of the year [103]

Financial Performance - Teva's Q2 2025 revenues remained flat at $4176 million compared to Q2 2024, but excluding Japan BV, revenues increased by 2%[87] - Non-GAAP EPS increased by 10% to $066 in Q2 2025 compared to $061 in Q2 2024[87] - Free cash flow increased significantly by 47% to $476 million in Q2 2025 from $324 million in Q2 2024[87] - The company is on track to achieve a 30% operating profit margin (OPM) by 2027 through its transformation program[85, 91] Product Performance - AUSTEDO U S revenues grew by 22% year-over-year to $495 million in Q2 2025[26] - UZEDY revenues increased significantly by 120% year-over-year to $54 million in Q2 2025[22, 31] - AJOVY global revenues increased by 31% year-over-year to $155 million in Q2 2025[22, 34] - Global generics revenues declined by 2%[22], and in local currency, global generics revenues decreased 5% vs Q2'24 including Japan BV[23] Pipeline and Strategy - The company expects to submit olanzapine LAI for U S NDA in Q4 2025[36, 55, 62] - Teva is targeting peak sales of $15-2 billion for the LAI franchise (UZEDY and olanzapine LAI)[102] - The company anticipates the start of Phase 3 trials for duvakitug in ulcerative colitis (UC) and Crohn's disease (CD) by Sanofi in Q4 2025[68] - Teva transformation in '25 well on track to deliver annualized ~20% of total $700 million savings[105]

Core Insights - Teva Pharmaceutical Industries Ltd. reported Q2 2025 results, highlighting a 10 consecutive quarters of year-over-year revenue growth, with revenues of $4.2 billion, a 1% increase in local currency terms excluding Japan BV revenues [3][4][8] - The company is on track to achieve a 30% operating profit margin by 2027 as part of its Pivot to Growth Strategy, with a focus on innovative product growth and transformation programs [3][5][6] Financial Performance - Q2 2025 revenues were $4,176 million, flat in U.S. dollars, or a decrease of 1% in local currency terms compared to Q2 2024 [8] - Gross profit increased to $2,102 million, a 4% rise compared to $2,024 million in Q2 2024, with a gross profit margin of 50.3% [10] - Non-GAAP diluted EPS for Q2 2025 was $0.66, an increase of 9% year-over-year [17] Product Performance - AUSTEDO revenues reached $498 million in Q2 2025, a 19% increase in local currency compared to Q2 2024, with an increased 2025 revenue outlook of $2,000 million - $2,050 million [3][6] - AJOVY global revenues were $155 million in Q2 2025, a 31% increase in local currency compared to Q2 2024, with an increased 2025 revenue outlook of $630 million - $640 million [3][6] - UZEDY revenues accelerated to $54 million in Q2 2025, a 120% increase compared to Q2 2024, with an increased 2025 revenue outlook of $190 million - $200 million [3][6] Segment Results - The United States segment reported revenues of $2,151 million, a 2% increase compared to Q2 2024, driven by higher revenues from innovative products [27][39] - The Europe segment saw revenues of $1,298 million, a 7% increase compared to Q2 2024, mainly due to higher revenues from AJOVY and generic products [42][50] - The International Markets segment experienced a 17% decrease in revenues to $495 million, primarily due to the divestment of the business venture in Japan [54][63] Cost Management and Savings - Teva's transformation programs are expected to generate ~$700 million in net savings by 2027, with ~$70 million targeted for 2025 [3][6] - Selling and Marketing expenses in Q2 2025 were $654 million, flat compared to Q2 2024, while General and Administrative expenses increased by 8% to $305 million [12] Outlook - The company reaffirmed its 2025 revenue outlook of $16.8 - $17.2 billion and adjusted EBITDA of $4.7 - $5.0 billion [67] - Non-GAAP diluted EPS outlook for 2025 is projected to be $2.50 - $2.65, reflecting a $0.05 increase at the low-end [67]